Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review
Table 2
Differences between survivors and nonsurvivors within 100 days.
Variable
Value, n (%)
value
Patient survived
Patient deceased
Gender (male)
9 (81.8%)
10 (100%)
0.262
Age
42.0 ± 10.3
44.5 ± 14.8
0.572
DM
2 (18.2%)
4 (40.0%)
0.268
Coinfection
CMV
4 (36.4%%)
3 (30.0%)
0.562
Bacteria
5 (45.5%)
5 (50.0%)
0.590
Leukemia relapse
3 (27.3%)
1 (10.0%)
0.331
GVHD
2 (18.2%)
6 (60.0%)
0.063
Hemoptysis
4 (36.4%)
9 (90.0%)
0.017a
WBC
2.4 (1.6–3.2)
1.3 (0.1–3.3)
0.307
NE
0.9 (0.4–1.9)
0.7 (0.08–1.4)
0.647
CRP
196.5 ± 92.5
255.7 ± 115.3
0.291
Multilobar
8 (72.7%)
9 (100%)
0.145
Cavitary infiltrate
6 (54.5%)
4 (44.4%)
0.500
Reversed halo sign
3 (27.3%)
3 (33.3%)
0.574
Pleural effusion
5 (45.5%)
5 (55.6%)
0.500
Pneumothorax
1 (9.1%)
0 (0.0%)
0.550
Rhizopus
7 (77.8%)
5 (50.0%)
0.220
Extrapulmonary involvementb
4 (36.4%)
2 (20.0%)
0.367
Surgery
2 (18.2%)
0 (0%)
0.262
a value is statistically significant. bWhen the observation time was extended to 365 days, no extrapulmonary involvement occurred in the survival group and all patients with extrapulmonary involvement died within 1 year. CMV: cytomegalovirus; NE: neutrophils.
